Indian government approves use of Moderna’s Covid-19 Vaccine Moderna

US biotech company Moderna has been given emergency use authorization from the Indian government for its Covid-19 Vaccine Moderna (mRNA-1273) in adults aged 18 years and older.

In this connection, the company has been given a registration certificate from the government along with permission to import the vaccine to India for restricted use in an emergency situation.

Stéphane Bancel – CEO of Moderna said: “I want to thank the government of India for this authorization, which marks an important step forward in the global fight against the pandemic.

“We are committed to making our COVID-19 vaccine available around the world.”

Indian government approves use of Moderna’s Covid-19 Vaccine Moderna
Indian government approves use of Moderna’s Covid-19 Vaccine Moderna. Photo courtesy of Spencer Davis from Pixabay.

Apart from Moderna’s vaccine, India had approved Covishield, Covaxin, and Sputnik V.

Moderna also has emergency (or other conditional, interim or provisional) authorization for use of the Covid-19 Vaccine Moderna from health agencies in 50 plus countries and also an emergency use listing (EUL) from the World Health Organization (WHO).

The Covid-19 Vaccine Moderna contains messenger RNA (mRNA), which is a genetic material. The vaccine has a small piece of the mRNA of the Covid-19 causing SARS-CoV-2 virus which informs cells in the body to make the virus’ distinctive “spike” protein.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics

Total
0
Shares
Related Posts
Read More

US pharma manufacturer Conagen acquires glycoproteins production platform

US pharma manufacturer Conagen has purchased a glycoproteins production platform – a fermentation-based technology for the production of glycoproteins used for making therapeutics, for an undisclosed price. The acquisition made from an undisclosed seller includes various patents covering the glycoproteins production platform and all related tangible assets, which are expected to place Conagen among the […]

The post US pharma manufacturer Conagen acquires glycoproteins production platform appeared first on PharmaNewsDaily.com.